Dr. Liu is a Principal at Longitude Capital. Prior to joining Longitude Capital in 2018, Dr. Liu was an Engagement Manager in the pharmaceuticals and medical products practice of McKinsey & Company. Dr. Liu is currently a board observer at Dascena and Quanta Therapeutics and previously served as a board observer at Inflazome, Talaris Therapeutics and Vera Therapeutics. Dr. Liu holds an MD from Stanford School of Medicine and a BS in Biomedical Engineering from The Johns Hopkins University.